Oral antidiabetic agents act through distinct pharmacological mechanisms to lower blood glucose: secretagogues (sulfonylureas) stimulate insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells, causing membrane depolarization, calcium influx, and calcium-mediated exocytosis of insulin-containing vesicles, a mechanism that requires functional beta cells to be effective. Biguanides instead increase peripheral insulin sensitivity and reduce endogenous insulin production, working independently of beta cell insulin secretion and therefore not causing hypoglycemia, while carrying a risk of lactic acidosis in patients with renal, hepatic, or respiratory impairment. This content belongs to pharmacology, specifically the pharmacologic management of type 2 diabetes, and illustrates how differing mechanisms of action determine differing efficacy conditions, side effect profiles, and clinical roles.
Oral antidiabetic agents act through distinct pharmacological mechanisms to lower blood glucose: secretagogues (sulfonylureas) stimulate insulin secretion by closing ATP-sensitive potassium channels …